Go Pro
→ Elon’s message for America (From Stansberry Research) (Ad)tc pixel Free QLGN Stock Alerts

Qualigen Therapeutics (QLGN) Financials

Qualigen Therapeutics logo
$0.88 -0.10 (-10.18%)
As of 07/16/2026
Compare
Annual Income Statements for Qualigen Therapeutics

Annual Income Statements for Qualigen Therapeutics

This table shows Qualigen Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 3/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -3.07 -9.18 -18 -4.75 -35 -1.79 -18 -19 -13 -6.35 -20
Consolidated Net Income / (Loss)		 -2.47 -8.79 -18 -7.86 -17 -1.79 -18 -21 -14 -6.26 -17
Net Income / (Loss) Continuing Operations		 -2.47 -8.79 -18 -7.86 -18 -1.79 -18 -14 -12 -6.16 -17
Total Pre-Tax Income 		-2.47 -8.79 -18 -7.86 -19 -1.78 -18 -14 -12 -6.15 -17
Total Operating Income		 -2.28 -8.91 -18 -7.90 -18 -1.50 -23 -15 -11 -5.76 -13
Total Gross Profit		 -0.20 -0.24 -0.27 0.00 0.00 4.07 1.32 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 5.56 5.65 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.20 0.24 0.27 0.00 0.00 1.49 4.33 0.00 0.00 0.00 0.00
Total Operating Expenses		 2.08 8.66 18 7.90 18 5.57 24 15 11 5.76 13
Selling, General & Admin Expense		 1.97 6.40 4.88 4.78 5.43 1.51 12 10 6.10 4.20 8.82
Research & Development Expense		 0.11 2.26 13 2.87 12 0.68 12 4.49 5.21 1.20 0.18
Other Operating Expenses / (Income)		 - - - 0.25 0.20 3.01 - - 0.00 0.36 4.20
Total Other Income / (Expense), net		 -0.19 0.12 0.06 0.04 -0.77 -0.28 4.77 0.87 -1.17 -0.39 -3.76
Interest Expense		 0.21 - - - - 0.28 -0.04 0.03 2.15 0.97 0.99
Interest & Investment Income		 0.00 0.04 0.06 0.04 0.13 - - - 0.00 0.13 0.74
Other Income / (Expense), net		 0.02 0.08 0.00 -0.00 -0.89 0.00 4.73 0.91 0.98 0.45 -3.52
Income Tax Expense		 - - - - - 0.00 0.01 0.01 -0.00 0.01 0.00
Net Income / (Loss) Discontinued Operations		 - - - - - - - -7.14 -1.29 -0.10 0.00
Preferred Stock Dividends Declared		 0.60 0.39 0.00 -3.11 17 - - - 0.00 0.09 2.56
Basic Earnings per Share		 ($6.79) ($3.11) ($2.04) ($4.95) ($3.66) ($0.32) ($6.10) - ($132.25) ($17.55) ($8.11)
Weighted Average Basic Shares Outstanding		 452.51K 2.95M 8.99M 2.21M 5.30M 5.60M 2.93M 3.84M 6.31M 361.59K 2.41M
Diluted Earnings per Share		 ($6.79) ($3.11) ($2.04) ($4.95) ($3.66) ($0.32) - - ($132.25) ($17.55) ($8.11)
Weighted Average Diluted Shares Outstanding		 452.51K 2.95M 8.99M 2.21M 5.30M 5.60M 29.33M 3.84M 101.45K 361.59K 2.41M
Weighted Average Basic & Diluted Shares Outstanding		 452.51K 2.95M 8.99M 2.21M 5.30M 5.60M 29.33M - 6.31M - 20.23M

Quarterly Income Statements for Qualigen Therapeutics

This table shows Qualigen Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.66 -2.45 -2.09 -1.58 -1.82 -0.86 -2.65 -1.69 -2.91 -12 -6.08
Consolidated Net Income / (Loss)		 -3.70 -2.45 -2.03 -1.58 -1.79 -0.86 -2.65 -1.69 -2.04 -11 -6.08
Net Income / (Loss) Continuing Operations		 -3.24 -2.47 -2.03 -1.48 -1.79 -0.86 -2.65 -1.69 -2.04 -11 -6.08
Total Pre-Tax Income 		-3.24 -2.48 -2.03 -1.48 -1.80 -0.85 -2.65 -1.69 -2.04 -11 -6.08
Total Operating Income		 -2.78 -2.27 -1.42 -1.74 -1.27 -1.33 -2.72 -1.68 -1.43 -7.36 -4.33
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 2.78 2.27 1.42 1.74 1.27 1.33 2.72 1.68 1.43 7.36 4.33
Selling, General & Admin Expense		 1.34 0.96 1.06 0.99 1.15 1.02 2.49 1.39 1.89 3.04 3.55
Marketing Expense		 - - - - - - 0.00 - - - 0.64
Research & Development Expense		 1.44 1.31 0.36 0.75 0.12 -0.04 0.03 0.02 0.11 0.03 0.01
Other Operating Expenses / (Income)		 - - 0.00 0.00 0.00 0.36 0.20 0.27 -0.57 4.29 0.14
Total Other Income / (Expense), net		 -0.46 -0.20 -0.61 0.26 -0.53 0.48 0.08 -0.00 -0.61 -3.23 -1.75
Interest Expense		 0.37 -0.22 0.14 0.26 0.41 0.16 0.07 0.07 0.65 0.19 0.00
Interest & Investment Income		 0.00 - 0.00 0.00 0.05 0.08 0.11 0.14 0.19 0.29 0.30
Other Income / (Expense), net		 -0.09 -0.42 -0.47 0.53 -0.17 0.56 0.04 -0.08 -0.15 -3.33 -2.05
Income Tax Expense		 0.00 -0.01 0.00 -0.00 -0.00 0.01 0.00 0.00 0.00 -0.00 0.00
Basic Earnings per Share		 - ($0.39) ($17.60) ($10.37) ($4.70) ($2.37) ($1.82) ($1.00) ($4.68) ($5.10) ($0.79)
Weighted Average Basic Shares Outstanding		 5.18M 6.31M 118.88K 152.07K 387.88K 361.59K 1.46M 1.68M 620.69K 2.41M 7.70M
Diluted Earnings per Share		 ($36.18) ($0.39) ($17.60) ($10.37) ($4.70) ($2.37) ($1.82) ($1.00) ($4.68) ($5.10) ($0.79)
Weighted Average Diluted Shares Outstanding		 101.05K 101.45K 118.88K 152.07K 387.88K 361.59K 1.46M 1.68M 620.69K 2.41M 7.70M
Weighted Average Basic & Diluted Shares Outstanding		 5.18M 6.31M 9.61M 12.16M 736.43K 0.00 - 1.70M 5.16M 20.23M 20.23M

Annual Cash Flow Statements for Qualigen Therapeutics

This table details how cash moves in and out of Qualigen Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 3/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 2.30 13 -8.77 16 -15 -0.54 -6.44 -11 -6.64 0.77 18
Net Cash From Operating Activities		 -1.16 -5.72 -15 -7.40 -13 0.06 -15 -13 -10 -6.33 -6.95
Net Cash From Continuing Operating Activities		 -1.16 -5.72 -15 -7.40 -12 -0.51 -15 -11 -9.09 -6.33 -6.95
Net Income / (Loss) Continuing Operations		 -2.47 -8.79 -18 -7.86 -17 -1.79 -18 -14 -12 -6.16 -17
Consolidated Net Income / (Loss)		 -2.47 -8.79 -18 -7.86 -17 -1.79 -18 -21 -14 -6.26 -17
Net Income / (Loss) Discontinued Operations		 - - - - - - - -7.14 - -0.10 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.87 3.31 1.36 0.89 -0.25 0.57 0.47 3.93 3.55 0.62 8.47
Changes in Operating Assets and Liabilities, net		 0.43 -0.25 1.75 -0.42 3.80 1.04 2.36 -0.64 1.11 -0.78 1.55
Net Cash From Investing Activities		 -0.00 -0.02 -0.01 -0.01 -6.97 -0.19 -0.14 -0.18 4.22 -1.91 -16
Net Cash From Continuing Investing Activities		 -0.00 -0.02 -0.01 -0.01 -6.97 -0.19 -0.14 0.00 0.00 -2.26 -16
Acquisitions		 - - - - - -0.19 -0.01 - - 0.00 -0.09
Purchase of Investments		 - - - 0.00 -6.97 - - - - -2.26 -1.91
Other Investing Activities, net		 - - - - - - 0.00 - 0.00 0.00 -14
Net Cash From Discontinued Investing Activities		 - - - - - - - -0.18 4.22 0.35 0.00
Net Cash From Financing Activities		 3.46 19 6.44 23 5.48 0.17 8.43 2.91 -0.55 9.01 41
Net Cash From Continuing Financing Activities		 3.46 19 6.44 23 5.48 0.17 8.43 2.91 -0.55 9.01 41
Repayment of Debt		 -0.03 0.00 - - - -0.14 -0.14 0.00 0.00 -2.50 -4.54
Issuance of Debt		 3.62 20 - - - 0.33 0.00 2.90 0.00 3.48 3.62
Issuance of Common Equity		 0.00 1.00 7.03 25 6.00 0.00 - - 0.00 7.62 42
Other Financing Activities, net		 -0.13 0.01 0.02 0.00 -0.52 -0.02 9.28 0.01 -0.55 0.42 0.00
Net Cash From Discontinued Financing Activities		 - - - - - - - 0.00 - 0.00 0.00
Cash Interest Paid		 0.00 0.00 - - - 0.09 0.00 0.00 0.00 0.09 1.01
Cash Income Taxes Paid		 0.00 0.00 0.08 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.00

Quarterly Cash Flow Statements for Qualigen Therapeutics

This table details how cash moves in and out of Qualigen Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 4.72 -5.55 -0.31 0.03 0.27 0.79 -1.14 0.30 38 -19 -13
Net Cash From Operating Activities		 0.93 -5.67 -0.78 -1.47 -1.80 -2.27 -1.59 -1.10 -2.14 -2.12 -4.50
Net Cash From Continuing Operating Activities		 -2.89 -1.84 -0.78 -1.47 -1.80 -2.27 -1.59 -1.10 -2.14 -2.12 -4.50
Net Income / (Loss) Continuing Operations		 -3.24 -2.47 -2.03 -1.48 -1.79 -0.86 -2.65 -1.69 -2.04 -11 -6.08
Consolidated Net Income / (Loss)		 -3.70 -2.45 -2.03 -1.58 -1.79 -0.86 -2.65 -1.69 -2.04 -11 -6.08
Non-Cash Adjustments To Reconcile Net Income		 1.18 0.25 0.65 -0.27 0.69 -0.45 0.12 0.19 -0.07 8.30 2.34
Changes in Operating Assets and Liabilities, net		 -0.38 0.36 0.60 0.28 -0.70 -0.96 0.94 0.29 -0.49 0.81 -0.76
Net Cash From Investing Activities		 4.23 0.24 0.00 0.35 -1.25 -1.01 -0.31 -1.21 -0.29 -14 -8.50
Net Cash From Continuing Investing Activities		 - - 0.00 - -1.25 -1.01 -0.31 -1.21 -0.29 -14 -8.50
Acquisitions		 - - - - - - 0.00 - - - -0.27
Purchase of Investments		 - - 0.00 - -1.25 -1.01 -0.31 -1.21 -0.29 -0.10 -10
Other Investing Activities, net		 - - - - - - 0.00 - - - 1.77
Net Cash From Financing Activities		 -0.44 -0.11 0.48 1.15 3.32 4.06 0.75 2.61 41 -3.25 -0.13
Net Cash From Continuing Financing Activities		 -0.44 -0.11 0.48 1.15 3.32 4.06 0.75 2.61 41 -3.25 -0.13
Repayment of Debt		 -0.44 0.44 0.48 -0.48 -2.00 -0.50 0.00 -0.13 -1.03 -3.38 -0.13
Issuance of Debt		 - - 0.00 1.48 2.00 - 0.75 2.75 - 0.13 0.00
Cash Interest Paid		 - - - - 0.06 0.03 0.00 - - 1.01 0.00
Cash Income Taxes Paid		 0.00 0.00 - - 0.01 -0.00 0.00 - - - 0.00

Annual Balance Sheets for Qualigen Therapeutics

This table presents Qualigen Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 16 7.24 23 15 2.80 29 23 19 2.03 4.69 31
Total Current Assets		 16 7.20 23 15 2.21 28 21 11 1.17 4.68 31
Cash & Equivalents		 16 7.05 23 7.81 1.70 24 18 3.17 0.40 1.17 19
Note & Lease Receivable		 - - 0.00 0.05 0.00 - - - 0.00 2.01 0.34
Prepaid Expenses		 0.19 0.16 0.17 0.42 0.51 2.68 1.38 1.37 0.76 1.50 1.03
Other Current Assets		 - - - - - - - - - 0.00 10
Plant, Property, & Equipment, net		 0.02 0.02 0.02 0.02 0.02 0.25 0.20 0.03 0.00 0.00 0.00
Total Noncurrent Assets		 0.01 0.01 0.01 0.02 0.57 0.65 1.84 8.24 0.87 0.00 0.33
Intangible Assets		 - - - - - 0.19 0.17 - - 0.00 0.31
Other Noncurrent Operating Assets		 0.01 0.01 0.01 0.02 0.57 0.47 1.66 0.00 0.87 0.00 0.01
Total Liabilities & Shareholders' Equity		 16 7.24 23 15 2.80 29 23 19 2.03 4.69 31
Total Liabilities		 1.35 3.13 2.71 5.93 1.70 11 6.27 10 4.14 2.01 3.33
Total Current Liabilities		 1.35 3.13 2.71 5.93 1.70 10 4.64 8.61 4.14 2.01 3.33
Short-Term Debt		 - - - - - 0.13 0.00 - 1.30 0.00 0.14
Accounts Payable		 0.74 1.90 2.24 4.51 1.42 0.50 0.89 0.62 2.22 1.57 1.26
Accrued Expenses		 0.61 1.22 0.45 1.41 0.18 0.75 1.79 0.86 0.56 0.17 0.14
Other Current Liabilities		 0.00 0.01 0.02 0.01 0.10 8.56 1.82 3.68 0.05 0.27 1.79
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.40 1.64 1.71 0.00 0.00 0.00
Commitments & Contingencies		 - - - - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 15 4.10 20 9.39 1.10 18 17 8.77 -2.10 2.68 28
Total Preferred & Common Equity		 15 4.10 20 9.39 1.10 18 17 7.24 -2.10 2.68 28
Preferred Stock		 0.00 0.00 5.13 8.08 1.53 0.00 - - 0.00 5.72 32
Total Common Equity		 15 4.10 15 1.31 -0.43 18 17 7.24 -2.10 -3.04 -3.89
Common Stock		 42 50 68 72 80 85 101 111 115 120 136
Retained Earnings		 -27 -45 -53 -70 -80 -67 -85 -103 -117 -123 -140

Quarterly Balance Sheets for Qualigen Therapeutics

This table presents Qualigen Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 4.32 1.00 0.53 2.31 2.85 3.96 43 24
Total Current Assets		 3.45 1.00 0.53 2.31 2.85 3.96 43 23
Cash & Equivalents		 2.07 0.09 0.12 0.39 0.03 0.33 39 6.20
Note & Lease Receivable		 - - - 1.30 2.23 3.31 4.35 0.39
Prepaid Expenses		 1.38 0.91 0.42 0.63 0.57 0.32 0.34 11
Other Current Assets		 - - - - 0.02 - - 6.20
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.87 0.00 0.00 0.00 0.00 0.00 0.00 0.42
Intangible Assets		 - - - - - - - 0.41
Other Noncurrent Operating Assets		 0.87 0.00 0.00 0.00 0.00 0.00 0.00 0.01
Total Liabilities & Shareholders' Equity		 4.32 1.00 0.53 2.31 2.85 3.96 43 24
Total Liabilities		 5.96 4.52 4.81 4.45 2.81 5.61 4.92 2.03
Total Current Liabilities		 5.96 4.52 4.81 4.45 2.81 5.61 4.92 2.03
Short-Term Debt		 - 1.02 1.67 1.43 0.84 3.62 3.24 0.00
Accounts Payable		 1.57 1.80 1.85 1.64 1.53 1.40 1.28 1.48
Accrued Expenses		 1.31 0.82 0.99 0.57 0.21 0.38 0.04 0.03
Other Current Liabilities		 3.08 0.88 0.30 0.81 0.23 0.21 0.36 0.52
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -1.64 -3.52 -4.28 -2.14 0.03 -1.65 39 22
Total Preferred & Common Equity		 -1.64 -3.52 -4.28 -2.14 0.03 -1.65 39 22
Preferred Stock		 - - - - 2.82 2.79 36 5.41
Total Common Equity		 -1.64 -3.52 -4.28 -2.14 -2.79 -4.44 2.45 16
Common Stock		 113 115 116 120 123 123 132 163
Retained Earnings		 -114 -119 -120 -122 -126 -127 -129 -146

Annual Metrics And Ratios for Qualigen Therapeutics

This table displays calculated financial ratios and metrics derived from Qualigen Therapeutics' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 3/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 7,792,433.00 10,730,362.00 49,506,521.00 5,734,639.00 45,713,862.00 29,117,100.00 42,110,182.00 5,181,058.00 736,431.00 5,160,383.00
DEI Adjusted Shares Outstanding		 0.00 62.00 86.00 396.00 459.00 3,657.00 58,234.00 84,220.00 103,621.00 736,431.00 5,160,383.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -148,042.31 -213,774.81 -12,002.12 -75,173.01 -488.79 -307.33 -221.33 -129.48 -8.62 -3.78
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -292.86% -108.91% 57.17% -137.99% 93.28% 0.00% 21.34% 25.41% 48.52% -214.53%
EBIT Growth		 0.00% -290.57% -108.93% 57.15% -137.64% 92.01% 0.00% 22.75% 25.44% 48.54% -214.53%
NOPAT Growth		 0.00% -290.44% -107.07% 57.16% -126.38% 91.60% 0.00% 34.87% 23.41% 49.03% -129.13%
Net Income Growth		 0.00% -255.28% -109.21% 57.23% -114.51% 89.40% 0.00% -17.53% 34.58% 54.51% -171.06%
EPS Growth		 0.00% 54.20% 34.41% 57.23% 26.06% 89.40% 0.00% 0.00% 0.00% 86.73% 53.79%
Operating Cash Flow Growth		 0.00% -394.35% -165.81% 51.36% -80.23% 100.43% 0.00% 10.07% 22.22% 38.59% -9.86%
Free Cash Flow Firm Growth		 0.00% 0.00% -76.72% 46.25% -61.07% 38.97% 0.00% 0.00% -39.16% 35.66% -144.63%
Invested Capital Growth		 0.00% 4.02% -159.41% 14.86% -116.07% 88.92% 0.00% -287.66% 68.04% 224.73% 482.29%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 42.04% 0.00% -100.00% 100.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -40.98% 40.44% -49.90% 90.37% 0.00% 12.30% -4.41% 26.59% -146.18%
EBIT Q/Q Growth		 0.00% 0.00% -40.97% 40.42% -49.72% 88.61% 0.00% 12.44% -4.46% 26.59% -146.18%
NOPAT Q/Q Growth		 0.00% 0.00% -40.29% 40.43% -42.60% 88.59% 0.00% 14.52% -1.19% 14.07% -84.16%
Net Income Q/Q Growth		 0.00% 0.00% -41.24% 40.60% -35.38% 85.45% 0.00% -25.79% 30.65% 20.30% -134.81%
EPS Q/Q Growth		 0.00% 0.00% -34.21% 40.60% -110.34% 85.45% 0.00% 0.00% 30.65% 14.26% 37.81%
Operating Cash Flow Q/Q Growth		 0.00% -25.11% -73.08% 43.17% -7.95% 100.36% 0.00% 4.85% -49.98% 34.97% 2.07%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 42.83% -5.85% 37.47% -100.00% 68.34% -271.06% 7.79% -80.90%
Invested Capital Q/Q Growth		 0.00% 0.00% 16.17% -6.34% -163.40% 68.33% 33.94% -136.88% 67.53% 237.42% 191.35%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 73.20% 23.37% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -22.72% -311.23% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -27.05% -400.85% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -27.00% -317.21% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -32.16% -316.55% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 90.42% 100.22% 100.03% 151.46% 110.26% 101.73% 100.00%
Interest Burden Percent		 109.42% 99.54% 99.67% 99.49% 99.32% 118.87% 99.76% 100.25% 120.82% 115.75% 101.47%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -144.77% -107.21% -195.71% -64.91% -114.32% -34.09% -102.68% -166.08% -413.03% -2,175.30% -110.78%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -448.26% -321.44%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -16.56% -69.03% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -19.73% -68.88% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 1,228.93% -1.18% -195.71% -51.17% -63.17% -2.86% -102.68% -156.04% -318.14% 19,432.57% 25.06%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.60 -6.24 -13 -5.53 -13 -1.05 -16 -10 -7.91 -4.03 -9.24
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -18.93% -280.60% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -30.32% -27.28% -47.86% -15.72% -23.22% -8.91% -11.59% -71.16% -100.43% -1,606.08% -75.86%
Return On Investment Capital (ROIC_SIMPLE)		 11.02% -42.46% -314.71% -27.49% -133.41% -95.66% -95.77% -117.86% 983.84% -150.55% -32.90%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 26.80% 76.63% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 27.17% 207.38% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 12.23% 207.24% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 100.25% 424.22% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.26 -8.83 -18 -7.90 -19 -1.50 -18 -14 -10 -5.32 -17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.25 -8.83 -18 -7.90 -19 -1.26 -18 -14 -10 -5.32 -17
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.90 7.09 1.09 2.63 0.00 1.88 0.75 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.90 7.09 1.09 2.63 0.00 1.90 0.75 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 2.20 5.51 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.08 2.82
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 2.17 2.41 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 209.91 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.62 0.00 0.01
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.69 -1.14 -1.22 -1.22 -1.27 -1.57 -1.06 -1.19 -1.75 -0.48 -0.66
Leverage Ratio		 1.73 1.16 1.24 1.24 1.29 1.73 1.49 1.65 3.17 11.68 1.17
Compound Leverage Factor		 1.90 1.15 1.23 1.23 1.28 2.05 1.49 1.66 3.83 13.52 1.19
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -161.53% 0.00% 0.51%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -161.53% 0.00% 0.51%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.52% 0.00% 0.00% 25.48% 86.04% 139.00% 0.00% 0.00% 0.00% 213.38% 113.35%
Noncontrolling Interests to Total Capital		 948.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 17.46% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -848.89% 100.00% 100.00% 74.52% 13.96% -39.00% 100.00% 82.54% 261.53% -113.38% -13.85%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.13 0.00 -0.01
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.09 0.00 1.15
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.16 0.00 -0.02
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.11 0.00 2.08
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 2.78 -10.96 0.26 -9.38 -35.46 -3.71 -9.53 -98.53 -38.89 -4.80
Noncontrolling Interest Sharing Ratio		 948.89% 98.90% 0.00% 21.17% 44.74% 91.60% 0.00% 6.04% 22.98% 993.33% 122.62%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.24 11.82 2.30 8.42 2.57 1.30 4.49 1.26 0.28 2.33 9.30
Quick Ratio		 2.19 11.68 2.25 8.36 2.50 1.00 3.96 0.37 0.10 1.59 5.91
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -6.28 -11 -5.97 -9.61 -5.87 0.00 -7.53 -10 -6.74 -16
Operating Cash Flow to CapEx		 -99,261.15% -33,658.24% -188,623.56% -96,352.07% -663,990.39% 822.07% -10,954.59% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -20.72 0.00 -218.97 -4.87 -6.98 -16.69
Operating Cash Flow to Interest Expense		 -5.42 0.00 0.00 0.00 0.00 0.20 0.00 -385.14 -4.79 -6.55 -7.03
Operating Cash Flow Less CapEx to Interest Expense		 -5.43 0.00 0.00 0.00 0.00 0.18 0.00 -385.14 -4.79 -6.55 -7.03
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.61 0.22 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 7.86 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 4.31 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 310.36 25.04 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.18 0.27 0.21 0.00 0.00 0.50 6.25 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 46.42 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 84.64 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 2,000.26 1,366.49 1,765.12 0.00 0.00 726.53 58.43 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 -726.53 72.64 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.18 -1.13 -2.94 -2.51 -5.41 -0.60 -0.97 -3.77 -1.21 1.50 8.76
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 -1.85 -5.81 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.05 -1.81 0.44 -2.91 4.81 0.00 -2.80 2.57 2.71 7.26
Enterprise Value (EV)		 0.00 -2.57 22 -1.20 -3.28 12 14 3.79 3.75 7.64 25
Market Capitalization		 0.00 13 29 16 3.44 12 31 5.43 2.85 3.10 12
Book Value per Share		 ($32.05) $1.88 $0.38 $0.30 $0.23 ($0.04) $0.57 $0.17 ($0.41) ($4.12) ($0.75)
Tangible Book Value per Share		 ($32.05) $1.88 $0.38 $0.30 $0.23 ($0.04) $0.56 $0.17 ($0.41) ($4.12) ($0.82)
Total Capital		 1.71 15 4.10 20 9.39 1.10 17 8.77 -0.80 2.68 28
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.30 0.00 0.14
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -2.75 -16 -7.05 -23 -15 -1.70 -18 -3.17 0.90 -1.17 -19
Capital Expenditures (CapEx)		 0.00 0.02 0.01 0.01 0.00 0.01 0.13 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.20 -1.17 -2.98 -2.54 -5.46 -1.19 -1.38 -0.95 -2.07 1.50 8.44
Debt-free Net Working Capital (DFNWC)		 1.55 15 4.07 20 9.34 0.51 16 2.21 -1.67 2.68 28
Net Working Capital (NWC)		 1.55 15 4.07 20 9.34 0.51 16 2.21 -2.97 2.68 28
Net Nonoperating Expense (NNE)		 0.88 2.55 5.47 2.33 4.35 0.74 2.03 11 5.85 2.23 7.72
Net Nonoperating Obligations (NNO)		 -2.89 -16 -7.05 -23 -15 -1.70 -18 -13 0.90 -1.17 -19
Total Depreciation and Amortization (D&A)		 0.01 0.00 0.01 0.01 -0.01 0.24 0.34 0.01 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -21.35% -24.36% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 9.23% 285.85% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 9.23% 285.85% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($848,750.00) ($388,750.00) ($255,000.00) ($62,500.00) ($45,750.00) ($13,250.00) ($305.00) ($242.50) $0.00 ($17.55) ($8.11)
Adjusted Weighted Average Basic Shares Outstanding		 4.00 69.00 93.00 395.00 723.00 3.66K 70.59K 76.81K 101.45K 0.00 2.41M
Adjusted Diluted Earnings per Share		 ($848,750.00) ($388,750.00) ($255,000.00) ($62,500.00) ($45,750.00) ($13,250.00) ($305.00) $0.00 $0.00 ($17.55) ($8.11)
Adjusted Weighted Average Diluted Shares Outstanding		 4.00 69.00 93.00 395.00 723.00 3.66K 70.59K 0.00 101.45K 361.59K 2.41M
Adjusted Basic & Diluted Earnings per Share		 ($848,750.00) ($388,750.00) ($255,000.00) ($62,500.00) ($45,750.00) ($13,250.00) ($305.00) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.00 24.00 72.00 177.00 424.00 766.00 58.67K 0.00 126.15K 0.00 20.23M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.60 -6.24 -13 -5.53 -13 -1.05 -16 -10 -7.91 -4.03 -9.24
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -18.93% -280.60% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -32.09% -316.46% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -10.59 0.00 0.00 0.00 0.00 -5.30 0.00 -402.75 -4.80 -5.50 -16.91
NOPAT to Interest Expense		 -7.48 0.00 0.00 0.00 0.00 -3.72 0.00 -300.39 -3.68 -4.18 -9.35
EBIT Less CapEx to Interest Expense		 -10.59 0.00 0.00 0.00 0.00 -5.32 0.00 -402.75 -4.80 -5.50 -16.91
NOPAT Less CapEx to Interest Expense		 -7.49 0.00 0.00 0.00 0.00 -3.74 0.00 -300.39 -3.68 -4.18 -9.35
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -24.97% -3.25% -25.92% 0.00% 0.00% -3.95% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Qualigen Therapeutics

This table displays calculated financial ratios and metrics derived from Qualigen Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 5,052,463.00 5,181,058.00 6,307,371.00 9,613,899.00 12,155,830.00 736,431.00 736,431.00 1,635,475.00 1,695,450.00 5,160,383.00 20,234,993.00
DEI Adjusted Shares Outstanding		 101,049.00 103,621.00 126,147.00 192,278.00 243,117.00 736,431.00 736,431.00 1,635,475.00 1,695,450.00 5,160,383.00 20,234,993.00
DEI Earnings Per Adjusted Shares Outstanding		 -36.19 -23.65 -16.59 -8.20 -7.49 -1.16 -3.59 -1.03 -1.71 -2.38 -0.30
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 10.54% -19.74% -17.61% 61.49% 49.93% 71.47% -41.64% -36.07% 21.86% -1,292.01% -137.65%
EBIT Growth		 8.92% -19.58% -17.61% 61.49% 49.93% 71.47% -41.64% -44.80% -9.89% -1,292.01% -137.65%
NOPAT Growth		 19.93% -6.22% 46.37% 51.67% 54.34% 41.48% -91.64% 3.28% -12.70% -453.42% -59.05%
Net Income Growth		 8.90% 71.28% 50.51% 55.05% 51.45% 65.07% -30.18% -6.90% -13.59% -1,138.16% -129.73%
EPS Growth		 0.00% 71.28% 0.00% 55.05% 51.45% -507.69% 89.66% 90.36% 0.43% -115.19% 56.59%
Operating Cash Flow Growth		 129.22% -153.45% 70.25% 49.65% -293.59% 59.98% -102.84% 25.53% -18.98% 6.48% -182.83%
Free Cash Flow Firm Growth		 184.91% -419.50% 192.57% 5.30% -129.22% 12.44% -221.68% -224.90% -45.46% -240.76% -234.04%
Invested Capital Growth		 -136.30% 68.04% -192.69% -193.18% 70.53% 224.73% 132.66% 159.89% 374.65% 482.29% 1,751.12%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 9.13% 6.07% 29.61% 35.90% -18.16% 46.49% -249.49% 38.42% 32.15% -853.24% 40.33%
EBIT Q/Q Growth		 9.13% 6.07% 29.61% 35.90% -18.16% 46.49% -249.49% 34.47% 10.32% -577.82% 40.33%
NOPAT Q/Q Growth		 22.86% 18.15% 37.48% -22.44% 27.13% -4.89% -104.77% 38.20% 15.09% -415.08% 41.15%
Net Income Q/Q Growth		 -5.34% 33.69% 17.04% 22.44% -13.80% 52.30% -209.20% 36.31% -20.91% -419.99% 42.63%
EPS Q/Q Growth		 -5.34% 33.69% 17.04% 22.44% -13.80% 49.57% 23.21% 45.05% -368.00% -8.97% 84.51%
Operating Cash Flow Q/Q Growth		 131.75% -710.02% 86.18% -88.18% -22.06% -26.09% 29.97% 30.91% -95.01% 0.89% -111.80%
Free Cash Flow Firm Q/Q Growth		 185.05% -134.66% 205.62% 0.93% -179.11% -3.83% -46.78% -3.59% 7.87% -143.23% -43.89%
Invested Capital Q/Q Growth		 -226.94% 67.53% -114.90% -5.19% 59.85% 237.42% -43.73% 92.89% 84.14% 191.35% 78.88%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 114.22% 98.89% 100.09% 106.68% 99.88% 100.94% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 112.81% 91.99% 107.12% 121.60% 125.09% 110.34% 98.54% 95.78% 129.14% 99.07% 95.25%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -277.99% -413.03% -872.50% 2,011.64% 415.38% -2,175.30% 394.01% 235.46% -39.69% -110.78% -186.25%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -448.26% -990.37% -567.40% -303.31% -321.44% -305.04%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -204.67% -318.14% -438.99% 4,654.16% 415.38% 19,432.57% 712.86% 346.23% -0.33% 25.06% -116.25%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.94 -1.59 -1.00 -1.22 -0.89 -0.93 -1.91 -1.18 -1.00 -5.15 -3.03
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -45.13% -14.75% -83.87% 61.23% -176.31% 54.55% 84.78% 20.96% -6.01% -53.44% -113.05%
Return On Investment Capital (ROIC_SIMPLE)		 118.55% 197.90% 39.83% 46.73% 125.67% -34.77% -217.54% -60.00% -2.40% -18.35% -13.87%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.87 -2.69 -1.90 -1.22 -1.44 -0.77 -2.69 -1.76 -1.58 -11 -6.38
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.87 -2.69 -1.90 -1.22 -1.44 -0.77 -2.69 -1.65 -1.12 -11 -6.38
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.96 0.00 1.54
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.96 0.00 1.58
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 5.08 7.46 7.14 3.41 2.82 1.56
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 -0.62 -0.29 -0.39 -0.67 0.00 25.46 -2.19 0.08 0.01 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.54 -1.75 -0.92 -1.21 0.27 -0.48 -0.50 -0.82 -0.95 -0.66 -0.25
Leverage Ratio		 1.91 3.17 6.32 -14.11 -1.75 11.68 -1.10 -0.76 1.26 1.17 1.22
Compound Leverage Factor		 2.16 2.92 6.77 -17.16 -2.19 12.88 -1.09 -0.73 1.62 1.16 1.16
Debt to Total Capital		 0.00% -161.53% -40.93% -64.04% -202.97% 0.00% 96.22% 184.11% 7.75% 0.51% 0.00%
Short-Term Debt to Total Capital		 0.00% -161.53% -40.93% -64.04% -202.97% 0.00% 96.22% 184.11% 7.75% 0.51% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 213.38% 322.00% 142.02% 86.40% 113.35% 24.73%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 261.53% 140.93% 164.04% 302.97% -113.38% -318.22% -226.13% 5.86% -13.85% 75.27%
Debt to EBITDA		 0.00 -0.13 -0.10 -0.19 -0.20 0.00 -0.14 -0.54 -0.48 -0.01 0.00
Net Debt to EBITDA		 0.00 -0.09 -0.09 -0.18 -0.14 0.00 -0.13 -0.49 5.23 1.15 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.16 -0.15 -0.29 -0.31 0.00 -0.17 -0.74 -0.65 -0.02 0.00
Net Debt to NOPAT		 0.00 -0.11 -0.13 -0.27 -0.22 0.00 -0.16 -0.67 7.08 2.08 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -39.97 -86.14 -176.01 -332.42 -76.85 -35.69 -64.33 -46.38 -2.04 -4.16 -0.89
Noncontrolling Interest Sharing Ratio		 26.38% 22.98% 49.69% -131.36% 0.00% 993.33% -80.92% -47.05% 99.16% 122.62% 37.58%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.58 0.28 0.22 0.11 0.52 2.33 1.01 0.71 8.83 9.30 11.57
Quick Ratio		 0.35 0.10 0.02 0.02 0.38 1.59 0.80 0.65 8.76 5.91 3.24
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 12 -4.16 4.39 4.43 -3.51 -3.64 -5.35 -5.54 -5.10 -12 -18
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 32.68 0.00 32.17 16.82 -8.59 -23.13 -72.62 -81.23 -7.81 -64.27 0.00
Operating Cash Flow to Interest Expense		 2.53 0.00 -5.74 -5.59 -4.41 -14.41 -21.59 -16.11 -3.28 -10.99 0.00
Operating Cash Flow Less CapEx to Interest Expense		 2.53 0.00 -5.74 -5.59 -4.41 -14.41 -21.59 -16.11 -3.28 -10.99 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.71 -1.21 -2.59 -2.73 -1.09 1.50 0.85 1.63 3.01 8.76 16
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -14 2.57 -5.39 -5.65 2.62 2.71 3.44 4.36 4.10 7.26 15
Enterprise Value (EV)		 3.03 3.75 3.00 2.64 3.12 7.64 6.32 12 10 25 25
Market Capitalization		 5.10 2.85 2.07 1.09 2.07 3.10 2.68 5.58 9.70 12 25
Book Value per Share		 ($0.32) ($0.41) ($0.68) ($0.68) ($0.18) ($4.12) ($3.79) ($6.03) $1.44 ($0.75) $0.81
Tangible Book Value per Share		 ($0.32) ($0.41) ($0.68) ($0.68) ($0.18) ($4.12) ($3.79) ($6.03) $1.44 ($0.82) $0.79
Total Capital		 -1.64 -0.80 -2.50 -2.61 -0.71 2.68 0.88 1.96 42 28 22
Total Debt		 0.00 1.30 1.02 1.67 1.43 0.00 0.84 3.62 3.24 0.14 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -2.07 0.90 0.93 1.55 1.05 -1.17 0.81 3.29 -36 -19 -6.20
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.58 -2.07 -2.59 -2.73 -1.09 1.50 0.84 1.63 3.00 8.44 15
Debt-free Net Working Capital (DFNWC)		 -2.51 -1.67 -2.50 -2.61 -0.71 2.68 0.87 1.96 42 28 21
Net Working Capital (NWC)		 -2.51 -2.97 -3.52 -4.28 -2.14 2.68 0.03 -1.65 39 28 21
Net Nonoperating Expense (NNE)		 1.75 0.86 1.04 0.36 0.91 -0.08 0.74 0.51 1.04 5.44 3.05
Net Nonoperating Obligations (NNO)		 -2.07 0.90 0.93 1.55 1.05 -1.17 0.81 3.29 -36 -19 -6.20
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.11 0.46 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($19.50) $0.00 ($10.50) $0.00 ($2.37) ($1.82) ($1.00) ($4.68) ($5.10) ($0.79)
Adjusted Weighted Average Basic Shares Outstanding		 101.05K 126.15K 118.88K 152.07K 736.43K 361.59K 1.46M 1.68M 620.69K 2.41M 7.70M
Adjusted Diluted Earnings per Share		 $0.00 ($19.50) $0.00 ($10.50) ($4.70) ($2.37) ($1.82) ($1.00) ($4.68) ($5.10) ($0.79)
Adjusted Weighted Average Diluted Shares Outstanding		 101.05K 2.03K 118.88K 152.07K 387.88K 361.59K 1.46M 1.68M 620.69K 2.41M 7.70M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($19.50) $0.00 $0.00 $0.00 ($2.37) $0.00 $0.00 $0.00 ($5.10) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 103.62K 126.15K 192.28K 243.12K 736.43K 0.00 0.00 1.70M 5.16M 20.23M 20.23M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.94 -1.59 -1.00 -1.22 -0.89 -0.93 -1.91 -1.18 -1.00 -5.15 -3.03
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -7.81 0.00 -13.88 -4.61 -3.52 -4.88 -36.48 -25.81 -2.41 -55.39 0.00
NOPAT to Interest Expense		 -5.30 0.00 -7.29 -4.62 -2.17 -5.92 -25.91 -17.29 -1.53 -26.70 0.00
EBIT Less CapEx to Interest Expense		 -7.81 0.00 -13.88 -4.61 -3.52 -4.88 -36.48 -25.81 -2.41 -55.39 0.00
NOPAT Less CapEx to Interest Expense		 -5.30 0.00 -7.29 -4.62 -2.17 -5.92 -25.91 -17.29 -1.53 -26.70 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Qualigen Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Qualigen Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Qualigen Therapeutics' net income appears to be on an upward trend, with a most recent value of -$16.97 million in 2025, rising from -$2.47 million in 2014. The previous period was -$6.26 million in 2024. See where experts think Qualigen Therapeutics is headed by visiting Qualigen Therapeutics' forecast page.

Qualigen Therapeutics' total operating income in 2025 was -$13.20 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $13.20 million

Over the last 10 years, Qualigen Therapeutics' total revenue changed from $0.00 in 2014 to $0.00 in 2025, a change of 0.0%.

Qualigen Therapeutics' total liabilities were at $3.33 million at the end of 2025, a 65.8% increase from 2024, and a 145.8% increase since 2015.

In the past 10 years, Qualigen Therapeutics' cash and equivalents has ranged from $401.80 thousand in 2023 to $23.98 million in 2020, and is currently $19.33 million as of their latest financial filing in 2025.

Over the last 10 years, Qualigen Therapeutics' book value per share changed from -32.05 in 2014 to -0.75 in 2025, a change of -97.6%.


Related Companies

Financial statements for NASDAQ:QLGN last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Central banks bought 710 tonnes - this fund pays monthly
Gold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...
Investors Alley | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely | Sponsoredtc pixel
Elon’s message for America
Elon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...
Stansberry Research | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
The only metrics you should watch as a day trader.
Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...
The TradingPub | Sponsoredtc pixel
Ex-CIA Insider: “Prepare for a Mid-Term Meltdown”
Former CIA and Pentagon advisor Jim Rickards - who correctly called the 2008 recession, Trump's 2016 election,...
Paradigm Press | Sponsoredtc pixel